Without profound changes in the scientific and regulatory environment, things will remain very tough for the agile disruptor -- relatively good news for established giants, presumably less good news for patients and for progress.

In his new book, “Phake: The Deadly World of Falsified and Substandard Medicines,” Roger Bate explores the underground trade in illegal medicines that kills over 100,000 people per year and supplants billions of dollars of real products.

Knowing where all our ingredients come from is the first step toward improving drug quality.

Consumers and doctors need to work more closely with pharmaceutical product developers.

Reviewing "The Myth of The Paperless Office" for the New Yorker in 2002, Malcolm Gladwell argued that if the computer had come first, and paper didn't exist, someone would have had to invent it.  Paper, it turns out, is a lot more useful than we typically appreciate.

In an attempt to protect poor, uninsured and underinsured Americans from unsafe drugs, we are making sure that some go without drugs completely. It is time the law was changed.

In case you missed it, AEI health expert Scott Gottlieb, MD explains the transformation of the pharmaceutical industry in a recently published piece (full text below). Drug discovery has become targeted, averse to bureaucracy, and focused on solving more difficult to cure, serious maladies.

The crisis in financing is having a chilling effect on biomedical innovation. As discussed in my last column, the main problem in our industry is that the sheer cost of drug development has become almost prohibitively expensive, effectively pricing almost everyone but the largest companies out of the market.